Mein Warenkorb

Fusion glycoprotein

Fusion glycoprotein Molekülinformation

Englischer NameRespiratory syncytial virus F proteinAnzahl der inverkehr gebrachten Arzneimittel3
Anzahl der klinischen Arzneimittel7Target-AliasProtein F,F,Fusion glycoprotein F0
Höchste Forschungs- und EntwicklungsphaseApproved
Englischer NameRespiratory syncytial virus F protein
Target-AliasProtein F,F,Fusion glycoprotein F0
Anzahl der inverkehr gebrachten Arzneimittel3
Anzahl der klinischen Arzneimittel7
Höchste Forschungs- und EntwicklungsphaseApproved

Fusion glycoprotein Produktliste

  • Attribut

    Antibody (2)Protein (1)

  • Produktbibliothek

    Online (3)

  • Spezies

    Mouse (2)Nipah virus (1)

  • Etikett

    Human IgG1 (2)His Tag (1)

  • Marker

    Unconjugated (2)Biotin-labeled (1)

Fusion glycoprotein Molekülhintergrund

Hendra virus (HeV) and Nipah virus (NiV) are henipaviruses discovered in the mid-to late 1990s that possess a broad host tropism and are known to cause severe and often fatal disease in both humans and animals. HeV and NiV infect host cells through the coordinated efforts of two envelope glycoproteins. The G glycoprotein attaches to cell receptors, triggering the fusion (F) glycoprotein to execute membrane fusion. G is a type II homotetrameric transmembrane protein responsible for binding to ephrinB2 or ephrinB3 (ephrinB2/B3) receptors. F is a homotrimeric type I transmembrane protein that is synthesized as a premature F0 precursor and cleaved by cathepsin L during endocytic recycling to yield the mature, disulfide-linked, F1 and F2 subunits. Upon binding to ephrinB2/B3, NiV G undergoes conformational changes leading to F triggering and insertion of the F hydrophobic fusion peptide into the target membrane. Subsequent refolding into the more stable post-fusion F conformation drives merger of the viral and host membranes to form a pore for genome delivery to the cell cytoplasm.

Fusion glycoprotein Molekülalias

Fusion glycoprotein, F protein, F, Nipah virus, Hendra virus

Klinische Arzneimittelinformation

Englischer NameForschungscodeForschungsphaseFirmaIndikationenKlinische Studie
Human Respiratory Syncytial Virus Monoclonal AntibodyTNM-001Phase 3 ClinicalZhuhai Trinomab Pharmaceutical Co LtdLower Respiratory Tract Infections; Respiratory Syncytial Virus Infections
Details
CPI-RSV-F VaccineBLB-201Phase 2 ClinicalBlue Lake Biotechnology IncRespiratory Syncytial Virus Infections
Details
ZiresovirRO-0529; AK-0529Phase 1 ClinicalF. Hoffmann-La Roche LtdRespiratory Syncytial Virus Infections
Details
RSV vaccine (Vaxart)Phase 1 ClinicalVaxart Biosciences IncRespiratory Syncytial Virus Infections
Details
GR-2102GR2102; GR-2102Phase 1 ClinicalRespiratory Syncytial Virus Infections
Details
Palivizumab biosimilar (mAbxience)Phase 1 ClinicalMabxience Sa
Details
RSM-01Phase 1 ClinicalBill & Melinda Gates Medical Research InstituteRespiratory Syncytial Virus Infections
Details

Inverkehr gebrachte Arzneimittelinformation

Englischer NameForschungscodeForschungsphaseFirmaFrühestes MarkennameFrühestes GenehmigungslandFrüheste IndikationFrüheste GenehmigungsgesellschaftFrüheste GenehmigungsdatumIndikationenKlinische Studie
NirsevimabAnti-RSV-mAb-D25; SP-0232; MEDI-8897; Anti-RSV MAb-YTEApprovedAimm Therapeutics, Sanofi, MedImmune IncBeyfortus, 乐唯初EURespiratory Syncytial Virus InfectionsSanofi Winthrop Industrie SA2022-10-31Lower Respiratory Tract Infections; Respiratory Syncytial Virus Infections
Details
PalivizumabABT-315; MEDI-493ApprovedAbbvie Inc, Medimmune LlcSynagisUnited StatesRespiratory Syncytial Virus InfectionsSwedish Orphan Biovitrum Ab (Publ)1998-06-19Bronchiolitis; Bronchopulmonary Dysplasia; Respiratory Syncytial Virus Infections; Heart Defects, Congenital; Infant, Premature, Diseases; Premature Birth
Details
Respiratory syncytial virus immune globulinRSV-IGIVApprovedMedimmuneRespiGamUnited StatesRespiratory Syncytial Virus Infectionsnull1996-01-01Respiratory Syncytial Virus Infections
Details
  • Molekülinformation
  • Produktliste
  • Inverkehr gebrachte Arzneimittelinformation
  • Klinische Arzneimittelinformation
Kontaktieren Sie uns